Attached files
file | filename |
---|---|
EX-10.9 - EX-10.9 - Spero Therapeutics, Inc. | spro-ex109_1873.htm |
EX-32.2 - EX-32.2 - Spero Therapeutics, Inc. | spro-ex322_9.htm |
EX-31.2 - EX-31.2 - Spero Therapeutics, Inc. | spro-ex312_7.htm |
EX-31.1 - EX-31.1 - Spero Therapeutics, Inc. | spro-ex311_6.htm |
EX-23.1 - EX-23.1 - Spero Therapeutics, Inc. | spro-ex231_1098.htm |
EX-21.1 - EX-21.1 - Spero Therapeutics, Inc. | spro-ex211_429.htm |
10-K - 10-K - Spero Therapeutics, Inc. | spro-10k_20171231.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Spero Therapeutics, Inc. (the “Company”) for the period ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: April 2, 2018 |
|
By: |
/s/ Ankit Mahadevia, M.D. |
|
|
|
Ankit Mahadevia, M.D. |
|
|
|
President and Chief Executive Officer (Principal Executive Officer) |